Michael A Kamm

Michael A Kamm's AcademicInfluence.com Rankings

Michael A Kamm

Chemistry

#1609

World Rank

#2373

Historical Rank

Chemical Engineering

#115

World Rank

#128

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Michael A Kamm's Degrees

PhD Chemical Engineering University of California, Berkeley
Masters Chemical Engineering University of California, Berkeley
Bachelors Chemical Engineering University of California, Berkeley

Why Is Michael A Kamm Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael A Kamm's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Infliximab maintenance therapy for fistulizing Crohn's disease. (2004) (2059)
Anal-sphincter disruption during vaginal delivery. (1993) (1588)
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. (2004) (1178)
Prospective comparison of faecal incontinence grading systems (1999) (1149)
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine (2004) (989)
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis (2003) (903)
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial (2017) (807)
Third degree obstetric anal sphincter tears: risk factors and outcome of primary repair (1994) (726)
Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. (2013) (645)
Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. (2006) (633)
Mechanisms of action of probiotics: Recent advances (2009) (588)
Modulation of human dendritic cell phenotype and function by probiotic bacteria (2004) (565)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. (2005) (564)
Characteristics of intestinal dendritic cells in inflammatory bowel diseases. (2005) (518)
Development of the Crohn's disease digestive damage score, the Lémann score (2010) (511)
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. (1993) (483)
Myths and Misconceptions About Chronic Constipation (2005) (476)
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease (1994) (469)
Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma (2000) (450)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (440)
Crohn's disease management after intestinal resection: a randomised trial (2015) (436)
Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk (2004) (411)
Pudendal nerve damage during labour: prospective study before and after childbirth * (1994) (404)
AGA technical review on anorectal testing techniques. (1999) (372)
Randomized controlled trial of biofeedback for fecal incontinence. (2003) (371)
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. (2007) (353)
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease (1997) (342)
Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease (2005) (341)
Bowel dysfunction in spinal-cord-injury patients (1996) (332)
Obstetric damage and faecal incontinence (1994) (328)
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study (2005) (320)
Obstetric Anal Sphincter Injury: Incidence, Risk Factors, and Management (2008) (316)
Most dysplasia in ulcerative colitis is visible at colonoscopy. (2004) (315)
Intestinal dendritic cells increase T cell expression of α4β7 integrin (2002) (311)
Sacral spinal nerve stimulation for faecal incontinence: multicentre study (2004) (310)
Inflammatory bowel disease in Asia: A systematic review (2012) (308)
Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). (1998) (298)
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease (2014) (297)
Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific (2014) (297)
Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease (2011) (285)
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. (2007) (275)
Diagnosis and treatment of chronic constipation – a European perspective (2011) (273)
Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis (2017) (268)
Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. (2019) (249)
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis (2006) (249)
Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. (2015) (247)
Outcome of colectomy for severe idiopathic constipation. (1988) (246)
Sacral nerve stimulation for intractable constipation (2010) (244)
Bowel dysfunction: a pathogenic factor in uterovaginal prolapse and urinary stress incontinence (1994) (242)
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. (2001) (242)
Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. (2015) (241)
The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria (2003) (236)
A multinational survey of prevalence and patterns of laxative use among adults with self‐defined constipation (2008) (229)
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. (2007) (226)
Double-blind randomised controlled trial of effect of metronidazole on pain after day-case haemorrhoidectomy (1998) (224)
Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults (1997) (220)
Randomised controlled trial shows that glyceryl trinitrate heals anal fissures, higher doses are not more effective, and there is a high recurrence rate (1999) (212)
Prospective study of the extent of internal anal sphincter division during lateral sphincterotomy (1994) (210)
Primary degeneration of the internal anal sphincter as a cause of passive faecal incontinence (1997) (206)
Permanent sacral nerve stimulation for fecal incontinence. (2000) (206)
Relationship of symptoms in faecal incontinence to specific sphincter abnormalities (2004) (191)
Tegaserod for the Treatment of Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Multinational Study (2005) (190)
Review article: defining remission in ulcerative colitis (2011) (190)
Biofeedback provides long term benefit for patients with intractable, slow and normal transit constipation (1998) (190)
Persistent pain and faecal urgency after stapled haemorrhoidectomy (2000) (186)
High incidence of inflammatory bowel disease in Australia: A prospective population‐based Australian incidence study (2010) (186)
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis (2008) (182)
Recent Advances in Characterizing the Gastrointestinal Microbiome in Crohn's Disease: A Systematic Review (2015) (180)
Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota* (2012) (176)
Endosonography of the anal sphincters: normal anatomy and comparison with manometry. (1994) (175)
Migration and Maturation of Human Colonic Dendritic Cells (2001) (174)
Postoperative recurrent luminal Crohn's disease: a systematic review. (2012) (173)
Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. (2002) (172)
Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review (2012) (171)
Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. (1994) (171)
Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome. (2004) (169)
Prospective Evaluation of Anti-Tumor Necrosis Factor Therapy Guided by Magnetic Resonance Imaging for Crohn's Perineal Fistulas (2009) (168)
Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying. (1996) (165)
Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging (2003) (165)
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting (2020) (164)
Rectal mucosal electrosensory testing—Evidence for a rectal sensory neuropathy in idiopathic constipation (1990) (162)
Lower gastrointestinal malignancy in Crohn's disease. (1994) (161)
Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Sodium Picosulfate in Patients With Chronic Constipation (2010) (159)
Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. (2011) (159)
Topical glyceryl trinitrate in the treatment of chronic anal fissure (1996) (159)
Genetics of inflammatory bowel disease in Asia: Systematic review and meta‐analysis (2011) (159)
Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. (1992) (157)
A comparison between electromyography and anal endosonography in mapping external anal sphincter defects (1990) (157)
Double-blind crossover study of sacral nerve stimulation for fecal incontinence (2000) (154)
Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects (2000) (154)
Mucosal Healing in Crohn's Disease: A Systematic Review (2013) (151)
Urbanization and the gut microbiota in health and inflammatory bowel disease (2018) (150)
Unsuspected sphincter damage following childbirth revealed by anal endosonography. (1991) (147)
A Randomized, Controlled Trial of Diathermy Hemorrhoidectomy vs. Stapled Hemorrhoidectomy in an Intended Day-Care Setting With Longer-Term Follow-Up (2003) (145)
Transperineal repair of symptomatic rectocele with Marlex mesh: a clinical, physiological and radiologic assessment of treatment. (1996) (144)
Three‐dimensional endoanal sonography in assessing anal canal injury (1999) (141)
Gastrointestinal transit and prolonged ambulatory colonic motility in health and faecal incontinence (1997) (140)
Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. (1997) (136)
Prucalopride, a systemic enterokinetic, for the treatment of constipation (2002) (133)
Association between specific mucosa‐associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: A pilot study (2015) (130)
Vasoactive intestinal polypeptide levels in sigmoid colon in idiopathic constipation and diverticular disease. (1990) (129)
Mechanisms of initiation and perpetuation of gut inflammation by stress (2002) (128)
Sacral nerve stimulation for faecal incontinence due to systemic sclerosis (2002) (127)
Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific (2018) (125)
Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis (2010) (125)
Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation. (1995) (125)
Proctographic features of anismus. (1995) (124)
Hereditary internal anal sphincter myopathy causing proctalgia fugax and constipation. A newly identified condition. (1991) (123)
Obstetric perineal trauma: An audit of training (1995) (122)
Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction (2004) (121)
Response to a behavioural treatment, biofeedback, in constipated patients is associated with improved gut transit and autonomic innervation (2001) (120)
Effect of probiotic strains on interleukin 8 production by HT29/19A cells (2002) (117)
Use of Probiotics in the Treatment of Inflammatory Bowel Disease (2003) (115)
Long‐term MRI‐guided combined anti‐TNF‐&agr; and thiopurine therapy for crohn's perianal fistulas (2012) (115)
Donor Recruitment for Fecal Microbiota Transplantation (2015) (114)
Pathophysiology and management of bowel dysfunction in multiple sclerosis (2001) (113)
Adverse Effects of Drugs Used in the Management of Constipation and Diarrhoea (1994) (113)
Fortnightly review : Faecal incontinence (1998) (111)
Clinical, physiological, and radiological study of a new purpose-designed artificial bowel sphincter. (1998) (110)
The normal range and a simple diagram for recording whole gut transit time (1992) (110)
First Prospective, Population-Based Inflammatory Bowel Disease Incidence Study in Mainland of China: The Emergence of “Western” Disease (2013) (109)
Topical tacrolimus in the treatment of perianal Crohn's disease: Exploratory randomized controlled trial (2007) (109)
Radioisotope determination of regional colonic transit in severe constipation: comparison with radio opaque markers. (1993) (108)
Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease (2011) (108)
Prospective assessment of accuracy of endoanal MR imaging and endosonography in patients with fecal incontinence. (2000) (107)
Disturbed gastric emptying in the short bowel syndrome. Evidence for a 'colonic brake'. (1993) (106)
Patients’ Views of a Colostomy for Fecal Incontinence (2005) (106)
Adalimumab for the treatment of fistulas in patients with Crohn’s disease (2009) (106)
Relationship between anatomic and symptomatic long-term results after rectocele repair for impaired defecation (1999) (106)
Female anal sphincter: age-related differences in asymptomatic volunteers with high-frequency endoanal US. (2002) (105)
Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting (2003) (105)
Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers (1998) (104)
Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis (2000) (104)
Clinical features of idiopathic megarectum and idiopathic megacolon. (1997) (104)
Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysis (2015) (102)
Preliminary examination of the relations between disease activity, illness perceptions, coping strategies, and psychological morbidity in Crohn's disease guided by the common sense model of illness (2011) (102)
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. (2014) (100)
Topical diltiazem and bethanechol decrease anal sphincter pressure without side effects (1999) (100)
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease (2009) (100)
Sacral Nerve Stimulation for Fecal Incontinence Related to Obstetric Anal Sphincter Damage (2008) (100)
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. (1997) (99)
Internal anal sphincter augmentation for fecal incontinence using injectable silicone biomaterial (2001) (98)
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence (2001) (98)
Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. (2016) (96)
Characterization of the Gastrointestinal Microbiota in Health and Inflammatory Bowel Disease (2012) (96)
Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). (1996) (94)
Injectable silicone biomaterial for faecal incontinence due to internal anal sphincter dysfunction (2002) (94)
DNA viruses in the pathogenesis of sporadic chronic idiopathic intestinal pseudo-obstruction. (1997) (92)
Ghrelin for the gastroenterologist: history and potential. (2003) (91)
Effect of extended MMX mesalamine therapy for acute, mild‐to‐moderate Ulcerative Colitis (2009) (91)
Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial (2009) (89)
Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health (2010) (89)
Dynamics of the Mucosa-Associated Flora in Ulcerative Colitis Patients during Remission and Clinical Relapse (2008) (88)
Serotonin and 5-hydroxyindoleacetic acid are increased in the sigmoid colon in severe idiopathic constipation. (1990) (88)
Proteus spp. as Putative Gastrointestinal Pathogens (2018) (87)
Bowel function and transit rate during the menstrual cycle. (1989) (87)
Does the St. Mark’s Incontinence Score Reflect Patients’ Perceptions? A Review of 390 Patients (2008) (86)
Internal anal sphincter repair (1997) (85)
Long-Term Results of Repeat Anterior Anal Sphincter Repair (2004) (85)
Predictive value of impaired evacuation at proctography in diagnosing anismus. (2001) (84)
Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence. (1994) (83)
Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study (2011) (82)
Antibodies to tumour necrosis factor α as treatment for Crohn's disease (2000) (82)
Impact of Ethnicity, Geography, and Disease on the Microbiota in Health and Inflammatory Bowel Disease (2013) (81)
Decreased density of interstitial cells of Cajal and neuronal cells in patients with slow‐transit constipation and acquired megacolon (2005) (80)
Laser Doppler measurement of rectal mucosal blood flow (1999) (80)
Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. (2020) (79)
Systematic review with meta‐analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation (2019) (78)
Short-term effects of sacral nerve stimulation for idiopathic slow transit constipation. (2002) (78)
Prospective evaluation of the treatment of solitary rectal ulcer syndrome with biofeedback (1997) (76)
Intestinal dendritic cells: Their role in bacterial recognition, lymphocyte homing, and intestinal inflammation (2010) (75)
Chromoendoscopy versus Narrow Band Imaging for Colonic Surveillance in Inflammatory Bowel Disease (2013) (75)
Medium‐term results of oral tacrolimus treatment in refractory inflammatory bowel disease (2007) (74)
Therapeutic strategies for the management of ulcerative colitis (2009) (73)
Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome (2013) (73)
Microbial Factors Associated with Postoperative Crohn’s Disease Recurrence (2017) (73)
Randomized, Controlled Trial of Anal Electrical Stimulation for Fecal Incontinence (2006) (73)
Management of Postoperative Crohn's Disease (2008) (73)
Microbial-gut interactions in health and disease. Interactions between dendritic cells and bacteria in the regulation of intestinal immunity. (2004) (72)
Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE) (2019) (72)
Laser Doppler flowmetry as a measure of extrinsic colonic innervation in functional bowel disease (2000) (72)
Psychological state and quality of life in patients having behavioral treatment (biofeedback) for intractable constipation (2002) (71)
Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases (2020) (71)
Incontinence: Causes, Management and Provision of Services (1995) (68)
Pathophysiology of diverticular disease. (2002) (67)
Disturbed gastric and small bowel transit in severe idiopathic constipation (1993) (66)
Up-Regulation of Collagen and Tissue Inhibitors of Matrix Metalloproteinase in Colonic Diverticular Disease (2004) (66)
Sacral nerve stimulation for faecal incontinence following a rectosigmoid resection for colorectal cancer (2005) (66)
Dynamic scanning defines a colonic defect in severe idiopathic constipation. (1988) (66)
Cinical, physiological, and radiological study of a new purpose-designed artifical bowel sphincter (1998) (66)
Vaginal endosonography (1994) (65)
Relationship between psychological state and level of activity of extrinsic gut innervation in patients with a functional gut disorder (2001) (65)
Abdominal rectopexy for complete prolapse: Prospective study evaluating changes in symptoms and anorectal function (1992) (64)
Visceral adiposity predicts post‐operative Crohn's disease recurrence (2017) (64)
Colectomy for idiopathic megarectum and megacolon. (1991) (63)
Behavioural therapy (biofeedback) for solitary rectal ulcer syndrome improves symptoms and mucosal blood flow (2004) (62)
Gender differences in the longitudinal pressure profile of the anal canal related to anatomical structure as demonstrated on three‐dimensional anal endosonography (2000) (62)
Magnetic resonance imaging of the pelvic floor in patients with obstructed defaecation (1997) (62)
Results of behavioral treatment (biofeedback) for solitary rectal ulcer syndrome (2001) (62)
Pathology of idiopathic megarectum and megacolon (1997) (61)
Randomized, controlled trial of topical phenylephrine for fecal incontinence in patients after ileoanal pouch construction (2000) (60)
MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations (2008) (59)
Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness (2017) (59)
Perianal fistulizing Crohn's disease: a call to action. (2008) (59)
Rapid changes in epidemiology of inflammatory bowel disease (2017) (58)
Treatment of impaired defecation associated with rectocele by behavioral retraining (biofeedback) (2000) (58)
Review article: the psychoneuroimmunology of irritable bowel syndrome – an exploration of interactions between psychological, neurological and immunological observations (2008) (58)
The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion (2008) (58)
Colorectal and anal motility during defaecation (1992) (58)
Prospective study of biofeedback treatment for patients with slow and normal transit constipation (1994) (58)
A Controlled Study of a Group Mindfulness Intervention for Individuals Living With Inflammatory Bowel Disease (2016) (57)
Proctocolectomy with restorative ileoanal reservoir for severe idiopathic constipation (1988) (57)
Psychological morbidity in women with idiopathic constipation (2000) (56)
Observation on the characteristics of stimulated defaecation in severe idiopathic constipation (1992) (55)
Sacral Nerve Stimulation for Fecal Incontinence Following Surgery for Rectal Prolapse Repair: A Multicenter Study (2005) (55)
Impact of Drug Therapy and Surgery on Quality of Life in Crohn's Disease: A Systematic Review (2015) (55)
Effect of probiotic strains on interleukin 8 production by HT29/19A cells. (2002) (55)
Prospective Assessment of the Clinical Value of Anorectal Investigations (2000) (54)
Transvaginal Versus Anal Endosonography for Detecting Damage to the Anal Sphincter (1997) (53)
Survey of laxative use by adults with self‐defined constipation in South America and Asia: a comparison of six countries (2009) (53)
Prospective assessment of the effect on quality of life of anti‐tumour necrosis factor therapy for perineal Crohn’s fistulas (2009) (52)
Pathology of the rectal wall in solitary rectal ulcer syndrome and complete rectal prolapse. (1996) (52)
Topical phenylephrine increases anal sphincter resting pressure (1999) (50)
Long‐term results of low‐dose intravenous ciclosporin for acute severe ulcerative colitis (2003) (50)
Clinical and surgical recurrence of Crohn's disease after ileocolonic resection in a specialist unit (2009) (50)
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study (2001) (50)
Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. (2000) (49)
Peptide-containing neurons in different regions of the submucous plexus of human sigmoid colon. (1992) (49)
Assessment of External Anal Sphincter Morphology in Idiopathic Fecal Incontinence with Endocoil Magnetic Resonance Imaging (2001) (47)
Abnormal visceral autonomic innervation in neurogenic faecal incontinence. (1993) (47)
Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. (2020) (47)
Steroid hormone abnormalities in women with severe idiopathic constipation. (1991) (47)
Fecal Biomarkers in the Diagnosis and Monitoring of Crohn's Disease (2014) (46)
Review article: population screening for colorectal cancer (2005) (45)
Effect of pregnancy on anal sphincter morphology and function (1993) (45)
Short-term Effects of Sacral Nerve Stimulation for IdiopathicSlow Transit Constipation (2002) (45)
Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice (2020) (45)
Faecal incontinence after childbirth (1997) (45)
A mechanistic role for leptin in human dendritic cell migration: differences between ileum and colon in health and Crohn's disease (2012) (45)
Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease. (2020) (44)
The acute effect of straining on pelvic floor neurological function (1994) (44)
Defined microbiota transplant restores Th17/RORγt+ regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas (2019) (44)
Enkephalins modulate inhibitory neuromuscular transmission in circular muscle of human colon via delta‐opioid receptors. (1990) (43)
Adalimumab sustains steroid‐free remission after 3 years of therapy for Crohn’s disease (2011) (43)
Constipation and its management (2003) (43)
Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation (2007) (42)
Idiopathic slow-transit constipation: an almost exclusively female disorder (2003) (42)
Circulating Gastrointestinal Hormone Abnormalities in Patients With Severe Idiopathic Constipation (1998) (42)
Prevalence of mental health disorders in inflammatory bowel disease: an Australian outpatient cohort (2015) (42)
Sacral nerve stimulation for the treatment of faecal incontinence related to dysfunction of the internal anal sphincter (2010) (41)
Safety, Tolerability, and Efficacy of Tegaserod over 13 Months in Patients with Chronic Constipation (2006) (41)
Abnormal internal anal sphincter fibrosis and elasticity in fecal incontinence (1995) (41)
Predictive value and clinical significance of myenteric plexitis in Crohn's disease (2009) (40)
Internal anal sphincter myopathy causing proctalgia fugax and constipation: further clinical and radiological characterization in a patient. (1997) (39)
Elucidation of Proteus mirabilis as a Key Bacterium in Crohn's Disease Inflammation. (2020) (39)
Non-surgical management of faecal incontinence. (2001) (39)
Development and validation of a patient‐reported disability measurement tool for patients with inflammatory bowel disease (2013) (38)
Prospective assessment of interobserver agreement for endoanal MRI in fecal incontinence (2001) (38)
Changes in anal anatomy following vaginal delivery revealed by anal endosonography (1999) (37)
Long-term outcome of sacral neuromodulation for chronic refractory constipation (2017) (37)
Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti‐tumor necrosis factor monotherapy (2013) (37)
Perineal examination as a predictor of underlying external anal sphincter damage (1997) (37)
Psychological well-being and quality of life in Crohn's disease patients with an ostomy: a preliminary investigation. (2013) (37)
Anorexia nervosa in gastrointestinal practice (2004) (36)
Faecal incontinence (2003) (36)
Influence of the subpubic arch angle on anal sphincter trauma and anal incontinence following childbirth (2002) (35)
Dynamic cystoproctography and physiological testing in women with urinary stress incontinence and urogenital prolapse. (1996) (34)
Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne (2012) (34)
Diagnostic Evaluation of Patients with Faecal Incontinence at a Specialist Institution (2004) (33)
The internal and sphincter--new insights into faecal incontinence. (1991) (32)
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. (2018) (32)
Partial colectomy and coloanal anastomosis for idiopathic megarectum and megacolon (1992) (32)
The Role of CT Colonography in Colorectal Cancer Screening (2005) (32)
Gastroenterologist perceptions of faecal microbiota transplantation. (2015) (32)
Perineal damage at delivery (1994) (31)
Randomised controlled trial of metronidazole to reduce pain after day case haemorrhoidectomy (1998) (31)
Chronic pelvic pain in women – gastroenterological, gynaecological or psychological? (1997) (31)
Exploration of Health Status, Illness Perceptions, Coping Strategies, and Psychological Morbidity in Stoma Patients (2014) (31)
The anal sphincter in idiopathic megarectum (1996) (31)
Quantitative and functional characteristics of intestinal‐homing memory T cells: analysis of Crohn's disease patients and healthy controls (2004) (31)
Evaluation of the intrinsic innervation of the internal anal sphincter using electrical stimulation. (1989) (30)
Reassessing artificial bowel sphincters (2000) (29)
Pilot study of two new injectable bulking agents for the treatment of faecal incontinence. (2008) (29)
Effect of intestinal resection on quality of life in Crohn's disease. (2015) (29)
Morbidity, mortality, and risk factors for esophagitis in hospital inpatients. (2000) (29)
Review article: maintenance of remission in ulcerative colitis. (2002) (28)
Contribution of gastrointestinal transit and pouch characteristics in determining pouch function. (1997) (27)
Asian perspectives in the management of inflammatory bowel disease: Findings from a recent survey (2010) (27)
Predictors for developing intestinal failure in patients with Crohn's disease (2013) (27)
Unwanted anal penetration as a physical cause of faecal incontinence. (1995) (26)
Permanent Sacral Nerve Stimulation for Treatment of Functional Anorectal Pain: Report of a Case (2007) (26)
Reproducible assessment of vaginal and rectal mucosal and skin blood flow: laser doppler fluximetry of the pelvic microcirculation. (2000) (26)
Electrogastrography in chronic intestinal pseudoobstruction (1996) (26)
Cancer surveillance strategies in ulcerative colitis: The need for modernization (2011) (26)
Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis (2008) (25)
Enteric innervation in idiopathic megarectum and megacolon (1996) (25)
Examination techniques for endosonography of the anal canal (1998) (24)
Inflammatory bowel disease in Asia (2010) (24)
925j Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study. (2013) (24)
Oesophageal epithelial innervation in health and reflux oesophagitis (1999) (24)
A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective (2010) (23)
Solitary rectal ulcer and complete rectal prolapse: one condition or two? (2004) (23)
Practical application of anti‐TNF therapy for luminal Crohn's disease (2011) (22)
Fecal microbiota transplantation therapy in Crohn's disease: Systematic review (2021) (22)
OP023 Optimising post-operative Crohn's disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study (2014) (22)
Inflammatory bowel disease serology in Asia and the West. (2013) (22)
A novel population of human CD56+ human leucocyte antigen D‐related (HLA‐DR+) colonic lamina propria cells is associated with inflammation in ulcerative colitis (2009) (22)
Relationship between gut-specific autonomic testing and bowel dysfunction in spinal cord injury patients (2009) (22)
Studies on the mechanisms of action of activated charcoal on theophylline pharmacokinetics (1987) (22)
Comparison of Fecal Inflammatory Markers in Crohn's Disease (2016) (21)
1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study (2012) (21)
600 Multi Donor Intense Faecal Microbiota Transplantation is an Effective Treatment for Resistant Ulcerative Colitis: A Randomised Placebo-Controlled Trial (2016) (21)
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure (2020) (21)
Diagnostic, pharmacological, surgical and behavioural developments in benign anorectal disease. (2003) (20)
Gastrointestinal transit in patients with idiopathic megarectum (1996) (20)
Intractable vomiting due to a brainstem lesion in the absence of neurological signs or raised intracranial pressure (1998) (20)
Recent developments in CT colonography. (2005) (20)
Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn’s Disease (2018) (20)
Prospective Evaluation of Intestinal Homing Memory T Cells in Ulcerative Colitis (2004) (20)
Review article: the management of constipation in adults. (1993) (19)
Thiopurine metabolite testing in inflammatory bowel disease (2016) (19)
The design of a two‐phase radiolabelled meal for gastric emptying studies (1991) (19)
Serologic antibodies in relation to outcome in postoperative Crohn's disease (2017) (19)
Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study (2006) (19)
Diltiazem lowers resting anal sphincter pressure: A potential low side-effect alternative to glycerl trinitrate (GTN) for fissures (1998) (18)
Specialist nurses in gastroenterology. (2002) (18)
Noninvasive imaging of the small bowel in Crohn's disease: The final frontier (2011) (18)
Constipation. Etiology, Evaluation and Management (1995) (18)
Comparison of Clinical Outcome Between Open and Percutaneous Lead Insertion for Permanent Sacral Nerve Neurostimulation for the Treatment of Fecal Incontinence (2009) (17)
Behavioural treatment (biofeedback) for constipation following hysterectomy (2000) (17)
Bowel dysfunction in young women with urinary retention. (1993) (17)
Left hemicolectomy with rectal excision for severe idiopathic constipation (1991) (17)
S1321 Stimulant Laxatives are Effective in Chronic Constipation: Multi-Center, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Bisacodyl (2010) (17)
Joint symptoms after restorative proctocolectomy in ulcerative colitis and familial polyposis coli. (1996) (17)
Sphincteroplasty for incontinence after surgery for idiopathic fistula in ano (1997) (17)
Exploration of Health Status, Illness Perceptions, Coping Strategies, Psychological Morbidity, and Quality of Life in Individuals With Fecal Ostomies (2017) (16)
Role of surgical treatment in patients with severe constipation. (1990) (16)
Inflammatory bowel disease cancer surveillance in a tertiary referral hospital: attitudes and practice (2014) (16)
Clinical case: chronic constipation. (2006) (16)
The small intestine and colon: scintigraphic quantitation of motility in health and disease (2004) (16)
Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (16)
The role of psychosocial factors in functional gut disease. (1998) (16)
Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. (2019) (16)
Faecal incontinence: common and treatable (2002) (15)
Adalimumab prevents post-operative Crohn's disease recurrence, and is superior to thiopurines: early results from the POCER study (2012) (15)
Results of stoma formation for idiopathic megarectum and megacolon (1992) (15)
Systematic review of the efficacy and safety of sacral nerve stimulation for faecal incontinence (2003) (15)
Distinct neurophysiological profiles in irritable bowel syndrome. (2011) (15)
Diet and gut microbiome in gastrointestinal disease (2021) (15)
A randomized controlled trial of CDP571, a humanized antibody to TNFA, in moderately to severely active Crohn's disease (2000) (14)
Dysplastic lesions in ulcerative colitis: Changing paradigms (2010) (14)
Gastrointestinal Transit: Pathophysiology and Pharmacology (1991) (14)
Luminal microbiota related to Crohn’s disease recurrence after surgery (2020) (14)
Variants in ACTG2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudo‐obstruction (2018) (14)
Bowel Control : Information and Practical Advice (1998) (13)
Outcome of hospital outpatient treatment of functional gastrointestinal disorders (2019) (13)
Symptomatic Gastroesophageal Reflux in Acutely Hospitalized Patients (2004) (13)
Drug management of ulcerative colitis. (1992) (13)
Assessment of the Predictive Value of a Bowel Symptom Questionnaire in Identifying Perianal and Anal Sphincter Trauma After Vaginal Delivery (2003) (13)
Pudendal Nerve Stimulation for Bowel Dysfunction in Complete Cauda Equina Syndrome (2014) (12)
Rectodynamics — quantifying rectal evacuation (1989) (12)
Differences Across Illness Perceptions in Inflammatory Bowel Disease and Their Relationships to Psychological Distress and Quality of Life (2017) (12)
Mesalamine with MMX™ technology for the treatment of ulcerative colitis (2008) (12)
Why the enteric nervous system is important to clinicians (2000) (12)
Magnetic resonance enterography for predicting the clinical course of Crohn's disease strictures (2020) (11)
Psychological morbidity in women with idiopathic constipation. (2000) (11)
Comparison of the Efficacy and Safety of SPD476, a Novel, Once-Daily, High-Dose Formulation of Mesalamine, and Asacol with Placebo for the Induction of Remission of Mild-Moderate Ulcerative Colitis: A Phase III Study (2005) (11)
Gut-Directed Pelvic Floor Behavioral Treatment for Fecal Incontinence and Constipation in Patients with Inflammatory Bowel Disease. (2018) (11)
Novel strain-level resolution of Crohn’s disease mucosa-associated microbiota via an ex vivo combination of microbe culture and metagenomic sequencing (2021) (11)
The effect of an antacid and food on the absorption of cimetidine and ranitidine (1990) (11)
Working Party report: defecation disorders. (1994) (11)
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease (2016) (11)
Delivery of care for functional gastrointestinal disorders: A systematic review (2020) (11)
Long Term Outcome of Multidisciplinary versus Standard Gastroenterologist Care for Functional Gastrointestinal Disorders. A Randomised Trial. (2021) (10)
Pemphigus vulgaris of the esophagus. (1988) (10)
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis (2009) (10)
Ghrelin enhances gastric emptying in diabetic gastroparesis (2005) (10)
Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates (2021) (10)
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. (2021) (10)
Quality of life in reflux and dyspepsia. Development and psychometric documentation of a disease-specific questionnaire (QOLRAD) (1998) (10)
Cost-effectiveness of Crohn's disease post-operative care. (2016) (10)
Relapsing eosinophilic myositis--a cause of pseudothrombophlebitis in an alcoholic. (1987) (10)
Ultrasonography shows no abnormality of pelvic structures in women with severe idiopathic constipation. (1989) (10)
Investigation of faecal incontinence. (2001) (9)
SPD476 Is a Novel, Once-Daily, High-Dose, Effective and Well Tolerated 5ASA Formulation for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis: A Phase III Study (2005) (9)
78 Incidence and Phenotype of Inflammatory Bowel Disease From 13 Countries in Asia-Pacific: Results From the Asia-Pacific Crohn's and Colitis Epidemiologic Study 2011-2013 (2016) (9)
Prucalopride (PRU) improves colonic transit and stool frequency in patients (PTS) with slow and normal transit constipation (2000) (9)
Entry criteria for drug trials of irritable bowel syndrome. (1999) (9)
Tu1164 Environmental Risk Factors in Inflammatory Bowel Disease in Asia-Pacific: A Population-Based Case-Control Study (2014) (9)
Surgery for idiopathic megarectum and megacolon (1991) (9)
Fecal incontinence. (2001) (9)
The gut microbiota: cause and cure of gut diseases (2018) (9)
Low dose interferon gamma for refractory Crohn's disease. (1997) (9)
Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn ' s Disease Following Surgery (2015) (9)
Outcome of behavioural treatment for idiopathic chronic constipation (2014) (8)
Novel drug therapies in inflammatory bowel disease. (1995) (8)
M1202 Effective Probiotic Treatment (VSL#3), But Not Placebo, in Acute Ulcerative Colitis Is Associated with Down-Regulation of Inflammatory Intestinal Dendritic Cells (2008) (8)
An extra-ordinary cause of megacolon (1997) (8)
Prevalence of disordered eating in adults with gastrointestinal disorders: A systematic review (2021) (8)
Bisacodyl and Sodium Picosulfate Improve Bowel Function and Quality of Life in Patients with Chronic Constipation—Analysis of Pooled Data from Two Randomized Controlled Trials (2017) (8)
Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review (2020) (8)
Review article: chronic active disease and maintaining remission in Crohn's disease. (2004) (8)
W1096 Results from An Open-Label Extension of CHARM: Steroid-Free Remission in Patients with Crohn's Disease Who Received Adalimumab Therapy for At Least 3 Years (2009) (7)
Evaluation of specific herpes DNA viruses in idiopathic megarectum and idiopathic megacolon (1998) (7)
Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy (2020) (7)
Primary and secondary disorders to gut muscle and nerve. (1996) (7)
Pharmacological treatment of irritable bowel syndrome--from concept to sales. (2002) (7)
Endoscopic Prediction of Crohn's Disease Postoperative Recurrence. (2021) (7)
Faecal incontinence. (1998) (7)
Gastric Compliance, Sensation, and the Relaxation Response to a Nitric Oxide Donor in Health and Reflux Oesophagitis (1999) (7)
A global consensus on the classi fi cation , diagnosis and multidisciplinary treatment of perianal fi stulising Crohn ’ s disease (2014) (6)
Tegaserod is effective in relieving the multiple symptoms of constipation: results from a 12-week multinational study in patients with chronic constipation (2003) (6)
The value of age of onset and rectal emptying in predicting the outcome of colectomy for severe idiopathic constipation (1992) (6)
Idiopathic constipation: any movement? (1992) (6)
Surgical management of severe idiopathic constipation: a review. (1991) (6)
Psychological Well-Being and Quality of Life in Crohn's Disease Patients With an Ostomy: A Preliminary Investigation (2013) (6)
Fulminant Crohn's colitis: When only an antibody will do (2007) (6)
Debate: Should Mesalamine Be Used in Crohn's Disease?: Comments and Conclusions (2005) (6)
Pharmacological modulation of gut mucosal and large vessel blood flow (2007) (6)
Intestinal pseudo-obstruction (2000) (6)
Magnification pan-chromoendoscopy remains the mainstay for colitis dysplasia detection and differentiation. (2007) (6)
Simple water‐based tacrolimus enemas for refractory proctitis (2019) (6)
Su2092 Clinical Risk Stratification Predicts Development of Endoscopic Recurrence After Crohn's Disease Surgery: Early Results From the POCER Study (2012) (6)
Systematic review: Pelvic floor muscle training for functional bowel symptoms in inflammatory bowel disease (2019) (5)
Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID‐19 pandemic (2021) (5)
Glyceryl trinitrate heals anal fissures, high doses do it quicker, but there is a high recurrence rate (1998) (5)
A prospective clinical, physiological and radiological study of anew purpose-designed artificial bowel sphincter (1998) (5)
Sustainability of Adalimumab in Fistula Healing and Response: 2-Year Data from CHARM and 12-Month Open-Label Extension Follow-Up Study: 1034 (2007) (5)
A Case of Factitious Colonic Bleeding (1990) (5)
Processed food affects the gut microbiota: The revolution has started (2020) (5)
Obstacles to Donor Recruitment for Faecal Microbiota Transplantation: Experiences From the FOCUS Study: 650 (2014) (5)
MMX™ Mesalamine Is Effective for the Maintenance of Ulcerative Colitis Remission in Both Left-Sided and Extensive Disease: 936 (2007) (5)
The surgical treatment of severe idiopathic constipation (1987) (5)
crossover study gastroparesis: a double blind, placebo controlled, Ghrelin enhances gastric emptying in diabetic (2008) (5)
Systematic review: efficacy of escalated maintenance anti‐tumour necrosis factor therapy in Crohn's disease (2021) (5)
Probiotic therapy for pouchitis and its endoscopic findings (2002) (5)
Anin vitro electrophysiological study of the colon from patients with idiopathic chronic constipation (1992) (5)
Effect of a novel prokinetic drug, RO93877, on bowel function and gastrointestinal transit in healthy volunteers (1997) (5)
M1805 Defining, Diagnosing and Treating Constipation: Attitudes Among Gastroenterologists and General Practitioners - Results of a Three Country Survey (2008) (4)
Strain population structure varies widely across bacterial species and predicts strain colonization in unrelated individuals (2020) (4)
P837 The common food additives sodium sulfite and polysorbate 80 have a profound inhibitory effect on the commensal, anti-inflammatory bacterium Faecalibacterium prausnitzii: the ENIGMA study (2019) (4)
Surgical management of hereditary pancreatitis: report of a case and presentation of a new family. (1994) (4)
A radiopaque marker technique for measuring gastrointestinal transit in subjects with an ileostomy (1996) (4)
A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive. (2021) (4)
Mesenteric dendritic cells from germ-free mice cause less T-cell stimulation but still induce α4β7 integrin (2007) (4)
Interventions to Improve Adherence to Preventive Care in Inflammatory Bowel Disease: A Systematic Review. (2021) (4)
Relationship between parity and anal manometry (1993) (4)
Tu1282 First Prospective, Population-Based Inflammatory Bowel Disease Incidence Study in China - the Emergence of “Western” Disease (2012) (4)
Su1318 Intestinal Resection in Crohn's Disease Is Associated With Significant and Durable Improvement in Health Related Quality of Life Although to a Lesser Extent in Women and Smokers. Results From the POCER Study (2014) (4)
Specialist Nurses in Gastroenterology (2002) (4)
T1131 Steroid-Free Remission Over 2 Years in Crohn's Patients Receiving Adalimumab: the Open-Label Extension of the CHARM Trial (2008) (4)
MMX™ mesalamine Therapy for the Induction of Remission Beyond 8 Weeks: How Long Before Symptom Resolution? (2008) (4)
Treatment with anti-TNFA antibody reduces expression of CD40 on lamina propria dendritic cells—an early and central step in reducing T cell driven inflammation (2000) (4)
An analysis of 65 patients with fecal incontinence due to obstetric injury (2003) (4)
P342 Adalimumab prevents post-operative Crohn's disease recurrence and is superior to thiopurines: E (2012) (4)
312 The First Validated Post-Operative Endoscopic Crohns Disease Index: The POCER Index. Identification of Key Endoscopic Prognostic Factors (2016) (4)
Sacral nerve stimulation for idiopthic slow transit constipation (2000) (3)
Controlled clinical trial of ranitidine in bleeding peptic ulcer. (1986) (3)
Prospective assessment of interobserver agreement for endoanal MRI in fecal incontinence (2001) (3)
W1228 Prospective Scheduled Magnetic Resonance Imaging (MRI) to Guide Perineal Crohn's Fistula Treatment with Infliximab, Adalimumab and Thalidomide (2008) (3)
Early surgical intervention in ulcerative colitis (2004) (3)
Immune response to food in Crohn's diseae: In vivo and in vitro assessment (1998) (3)
The results of stoma formation in severe idiopathic constipation (1992) (3)
Motility and functional diseases of the large intestine (1993) (3)
Biofeedback, not laxatives, improves symptoms, transit and autonomic tone in functional constipation (2003) (3)
Post-Operative Crohn's Disease Recurrence: Impact of Endoscopic Monitoring and Treatment Step-up on Outcome (2011) (3)
Development and Validation of Surveys to Estimate Food Additive Intake (2020) (3)
The gut microbiota and gut disease (2021) (3)
Prevalence of genito‐urinary symptoms in patients with disordered defecation (1994) (3)
DOP81 Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s disease (2019) (3)
Microscopic colitis: Widening the definition (1995) (3)
Fundal gastritis as a potential cause of reflux oesophagitis. (2000) (3)
Speed of onset of oesophageal acid reduction with different proton‐pump inhibitors in patients with reflux oesophagitis (1998) (3)
W1162 Corticosteroids Increase Interleukin-10 and Inhibit Interleukin-12p40 Production By Intestinal Dendritic Cells in Acute Ulcerative Colitis - Novel Mechanisms of Therapy (2008) (3)
The small intestine and colon (1993) (3)
Motility and functional diseases including diverticular disease (1992) (3)
W1201 Production of IL-10 By Colonic Dendritic Cells Is Associated with Higher Concentrations of Faecal Microbiota in Patients with Active Crohn's Disease (2008) (3)
Su1994 – The Common Food Additives Sodium Sulfite and Polysorbate 80 Have a Profound Inhibatory Effect on the Commensal, Anti-Inflammatory Bacterium Faecalibacterium Prausnitzii. the Enigma Study (2019) (3)
Prospective Evaluation of Early Post-Operative Crohn's Recurrence in the Presence of Optimal Drug Therapy – Is Endoscopic Evaluation Worthwhile? (2011) (2)
MMX Mesalamine Is Well Tolerated in Patients with Active Mild-to-Moderate Ulcerative Colitis: Pooled Analysis of Adverse Events from Three Randomized Studies (2006) (2)
T1217 A Novel Population of CD56+ HLA-DR+ Colonic Lamina Propria Cells Is Associated with Inflammation in Ulcerative Colitis (2008) (2)
Non-invasive Serological Monitoring for Crohn’s Disease Postoperative Recurrence (2022) (2)
P043 Long-Term Steroid-Free Remission in Crohn's Patients Receiving Adalimumab: The Charm Trial (2008) (2)
Long-Term Remission Rates in Patients with Mild-to-Moderate Ulcerative Colitis Who Require an MMX™ Mesalamine Dose Increase To Induce Initial Remission: 937 (2007) (2)
A winking anus may signify spinal injury (2001) (2)
Determinants of long‐term function and general well‐being in patients with an ileoanal pouch (2020) (2)
Neuropeptides in the internal anal sphincter in neurogenic faecal incontinence (1993) (2)
PROBIOTIC BACTERIAL DNA INDUCES INTERLEUKIN-10 PRODUCTION BY HUMAN DENDRITIC CELLS VIA TOLL-LIKE RECEPTOR-9 (2012) (2)
Once- or Twice-Daily MMX™ Mesalamine for the Maintenance of Remission of Mild or Moderate Ulcerative Colitis: 939 (2007) (2)
998 Faecal Calprotectin Is Superior to Faecal Lactoferrin and S100A12 As a Surrogate Marker for Post-Operative Crohn's Disease Endoscopic Recurrence. Prospective Longitudinal Endoscopic Validation. Results From the POCER Study (2014) (2)
P300 Crohn’s Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. The STRIDENT Randomised Controlled Trial (2021) (2)
P083 - Steroid-free remission in patients with Crohn's disease who received adalimumab therapy for at least 3 years: long-term results from CHARM (2009) (2)
MMX Mesalamine, a Novel Formulation of 5-ASA, Effectively Induces the Remission of Active Mild-to-Moderate Ulcerative Colitis in Men and Women: 1103 (2006) (2)
Impact of Steroid Discontinuation on Health Care Resource Utilization in Crohn's Disease: 890 (2007) (2)
DOP064 Faecal calprotectin is superior to faecal lactoferrin and S100A12 (2014) (2)
Long-Term Adalimumab Treatment Is Associated with Sustained Fistula Healing in Patients with Moderate to Severe Crohnʼs Disease: 1067 (2008) (2)
Serotonin, but not noradrenaline, levels are increased in the circular muscle and mucosa of the sigmoid colon from patients with severe idiopathic constipation (1989) (2)
Probiotic bacteria induce maturation and modulate cytokine production by human dendritic cells (2003) (2)
597 Serological Antibodies for the Prediction of Post-Operative Recurrent Crohn's Disease Results From the POCER Study (2015) (2)
Gut-focussed behavioural treatment (biofeedback) for constipation and faecal incontinence in patients with Multiple Sclerosis (2000) (2)
Four week treatment of metronidazole and ciprofloxacin markedly decreases refractory pouchitis and improves the quality of life (2001) (2)
Antagonist: Early surgical intervention in ulcerative colitis. (2004) (2)
P124 Sustainability of Adalimumab in Improving the Quality of Life of Patients with Fistulizing Crohn's Disease: 2-Year Data from Charm (2008) (2)
Childhood antibiotics as a risk factor for Crohn's disease: The ENIGMA International Cohort Study (2022) (2)
Modification of host cell function by normal flora – a molecular perspective (2002) (2)
T2020 No Clinical Benefit of Prebiotics in the Treatment of Active Crohn's Disease: A Double-Blind, Randomised, Placebo-Controlled Trial (2010) (2)
M1146 Long-Term Outcome and Adverse Events in Crohn's Disease Patients Treated with Infliximab At a Single Tertiary Referral Center Over 9 Years (2008) (2)
Acute hepatitis due to etretinate (1988) (2)
MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: An evidence-based medicine analysis: P-0049. (2007) (2)
P834 Proteus is a key candidate in the pathogenesis of Crohn’s disease: mucosa, stool genomics and functional analysis: the ENIGMA study (2019) (2)
S1063 Sustained Improvement in Quality of Life for Patients with Fistulizing Crohn's Disease Treated with Adalimumab: 3-Year Data from CHARM (2009) (2)
P834 Proteus is a key candidate in the pathogenesis of Crohn’s disease: mucosa, stool genomics and functional analysis: the ENIGMA study (2019) (2)
Challenges in functional bowel disease. (2001) (2)
Sa2057 Probiotic Bacteria VSL#3 Alter Visceral Sensitivity and Mucosa-Associated Intestinal Microbiota in Patients With Irritable Bowel Syndrome (2012) (2)
The Effect of Prolonged Therapy with MMX™ Mesalamine in Patients with Acute, Mild-to-Moderate Ulcerative Colitis: 940 (2007) (2)
MMX Mesalamine for the Treatment of Active Mild-to-Moderate Ulcerative Colitis: An Evidence-Based Medicine Analysis (2006) (2)
P019 LONG-TERM FISTULA HEALING AND RESPONSE WITH ADALIMUMAB TREATMENT: 2-YEAR DATA FROM CHARM INCLUDING 1-YEAR OPEN-LABEL EXTENSION (2008) (2)
P057 MMX Mesalazine is an Effective Treatment for Men And Women With Mild-To-Moderate, Active Ulcerative Colitis (2007) (2)
Functional disorders of the colon and anorectum (1995) (2)
Topical phenylephrine increases anal sphincter resting pressure: A possible treatment for faecal incontinence (1998) (2)
P186 Intestinal Cytokine Production by Dendritic Cells in Acute Ulcerative Colitis - An Immunoregulatory Role? (2007) (1)
Su1301 Incidence and Phenotype of Inflammatory Bowel Disease From 2012-2013 Across 9 Countries in Asia: Results From the 2012 Access Inception Cohort (2015) (1)
Accuracy of point‐of‐care intestinal ultrasound for Crohn's disease (2020) (1)
Induction of mucosal healing in mild-to-moderate ulcerative colitis in patients treated with MMX mesalamine: established versus newly diagnosed disease: P-0096. (2009) (1)
The host response to the normal intestinal flora (2002) (1)
Crohn's Disease Phenotype at Diagnosis is More Severe in the East (China) Than the West (Australia) and is Managed Differently. (2011) (1)
How to treat: Faecal incontinence (2003) (1)
DOP086 Intestinal resection in Crohn's disease is associated with significant and durable improvement in health related quality of life although to a lesser extent in women and smokers. Results from the POCER study (2014) (1)
MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: An evidence-based medicine analysis (2007) (1)
4 CROHN'S DISEASE PATHOBIONT ENTEROBACTERIACEAE GROWTH IS MODULATED BY FOOD ADDITIVES AND OXYGEN AVAILABILITY: FACTORS IN PATHOPHYSIOLOGY AND RECURRENCE. THE ENIGMA STUDY. (2020) (1)
Occult anal sphincter damage following manual disimpaction demonstrated by anal ultrasonography (1994) (1)
Defining optimal care for functional gut disorders - Multi-disciplinary versus standard care: A randomized controlled trial protocol. (2019) (1)
Imaging predicts the results from anterior external anal sphincter repair following obstetric trauma (2001) (1)
Dendritic cells (DC) differ between the small intestine and colon: Expression of the chemokine receptor CCR7 suggests that small intestine DC traffic constitutively, colonic DC only in inflammation (2003) (1)
NOTICE OF WITHDRAWAL (2006) (1)
Editorial: treating strictures in inflammatory bowel disease (2018) (1)
Sa1913 CONSENSUS GUIDELINES FOR THE REGULATION, PRODUCTION AND USE OF FECAL MICROBIOTA TRANSPLANTATION IN CLINICAL PRACTICE (2020) (1)
604 FOOD ADDITIVES ENHANCE PRO-INFLAMMATORY BACTERIAL GROWTH IN CROHN'S DISEASE MUCOSA-ASSOCIATED MICROBIOTA. THE ENIGMA STUDY. (2021) (1)
Gut microbiota bacterial strain richness is species specific and limits therapeutic engraftment (2022) (1)
Optimal delivery of care for functional gastrointestinal disorders: Randomized controlled trial of standard gastroenterologist-only care versus multidisciplinary care (MANTRA study) (2019) (1)
264 What Causes Recurrence of Crohn's Disease After Intestinal Resection? A Prospective Evaluation of Microbiota, Smoking and Anti-TNF Therapy. Results From the POCER Study (2015) (1)
Impact of long-term Adalimumab treatment on fistula healing in patients with moderate to severe Crohnʼs Disease: P-0072. (2008) (1)
P849 Urease-positive proteobacteria in Crohn’s disease identified by novel ex vivo mucosal microbe culture combined with metagenomic sequencing (MC-MGS): the ENIGMA study (2019) (1)
Sa513 FOOD AS A RISK FACTOR FOR THE DEVELOPMENT AND PERPETUATION OF CROHN'S DISEASE.AN INTERNATIONAL CASE-CONTROL STUDY OF FOOD AND FOOD ADDITIVE INTAKE FROM BIRTH TILL NOW. THE ENIGMA STUDY. (2021) (1)
Immune sensitization to food and bacteria in Crohn's disease (1998) (1)
Is targeting locus of control a desirable outcome of biofeedback in functional constipation (2007) (1)
S1328 Patients Can Self-Manage Their Stimulant Laxative Dose to Achieve Effective Relief of Chronic Constipation, as Demonstrated in Two Randomized Trials (2010) (1)
Induction of clinical and endoscopic remission in mild-to-moderate ulcerative colitis in patients treated with MMX® mesalamine: established versus newly diagnosed disease: P-0092. (2009) (1)
W1114 Methotrexate in Thiopurine Refractory Crohn's Disease - a Retrospective Cohort Study (2009) (1)
OP019 In faecal microbiota transplantation (FMT) for ulcerative colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short-chain fatty acid production are associated with remission (FOCUS study) (2018) (1)
P-107 Adalimumab Therapy Achieves Clinical Remission and Response at Week 26 in Chinese Patients with Crohn's Disease (2016) (1)
P260 Point of Care Ultrasound (POCUS) when performed by gastroenterologists with 200 supervised scans is accurate and clinically useful for patients with Crohn’s disease (2018) (1)
Anorectal physiology and pathology. (1991) (1)
Long‐term outcomes of perianal fistulizing Crohn's disease in the biologic era (2020) (1)
Post-Operative Crohn's Disease Recurrence is Associated with Specific Changes in the Faecal Microbiome and Potential Pathogenic and Protective Roles (2017) (1)
Comparison of the risk of Crohn's disease postoperative recurrence between modified Rutgeerts score i2a and i2b categories: an individual patient data meta-analysis. (2022) (1)
Modification of the intestinal flora (2002) (1)
409 RANDOMISED TRIAL OF MULTI-DISCIPLINARY VERSUS STANDARD GASTROENTEROLOGIST CARE FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (2020) (1)
Tu1847 – Urease-Positive Proteobacteria in Crohn's Disease Identified by Novel Ex-Vivo Mucosal Microbe Culture Combined with Metgenomic Sequencing (MC-MGS). the Enigma Study (2019) (1)
Topical application of a nitric oxide donor reduces internal anal sphincter tone Therapeutic implications (1993) (1)
Rectal sensation, the rectoanal reflex, and faecal incontinence (1988) (1)
459 CROHN'S DISEASE STRICTURES RESPOND TO DRUG TREATMENT AND TREAT-TO-TARGET INTENSE COMBINATION THERAPY IS MORE EFFECTIVE THAN STANDARD ANTI-TNF THERAPY. THE STRIDENT RANDOMISED CONTROLLED TRIAL. (2021) (1)
T1218 Intestinal Dendritic Cells in Ulcerative Colitis Have Altered CD103 (Alpha-E) Expression - in Support of Dysregulation in Gut-Homing (2008) (1)
Smokers with active crohn's disease have differences in the concentration and proportion of key bacterial groups of the faecal microbiota (2008) (1)
Processed Food as a Risk Factor for the Development and Perpetuation of Crohn’s Disease—The ENIGMA Study (2022) (1)
Evaluation of Helicobacter pyloni in reflux oesophagitis and Barrett's oesophagus (1)
Mo1799 – Utility of a Simple Blood Test for Mucosal Healing Monitoring is Accurate in Post-Operative Crohn’s Disease (2019) (1)
Abdominal and pelvic abscesses in Crohn's disease: Results of non-invasive and surgical management (1995) (1)
Letter: tofacitinib in biologic‐experienced ulcerative colitis—a single‐centre real‐world experience in Australia (2021) (1)
Intestinal homing memory T lymphocytes produce increased tumour necrosis factor-alpha during relapse of ulcerative colitis: Prospective study of patients in remission and at relpase (2003) (1)
P006 - Sustainability of adalimumab in improving the quality of life of patients with fistulizing Crohn's disease: 3-year data from CHARM (2009) (1)
Pelvic floor behavioral treatment for fecal incontinence and constipation in quiescent inflammatory bowel disease (2022) (1)
A pharmaceutical composition for the treatment of fecal incontinence (1997) (0)
Dendritic cell (DC) regulation of natural killer T cells may be altered in Crohns disease inflammation: Loss of MHC class I-like CD1 molecules from mucosal dendritic cells (2003) (0)
What causes post-operative Crohn's disease recurrence? Evaluation of gut microbiota, anti-TNF non-response and smoking (2015) (0)
P772 Development and validation of tools to assess food additive intake: the ENIGMA study (2019) (0)
Adalimumab Therapy maintains meaningful rates of steroid-free remission in patients with Crohnʼs Disease for up to 3 Years of Therapy: Results From an Open-Label Extension of CHARM: P-0117. (2009) (0)
DRUG MANAGEMENT OF ULCERATIVE COLITIS. REPLY (1992) (0)
552: DEEP CHARACTERIZATION OF THE MUCOSA-ASSOCIATED MICROBIOTA IN ASIAN AND WESTERN POPULATIONS REVEALS ACIDAMINOCOCCUS OCCUPIES A KEY NICHE IN THE NITROGEN ECONOMY OF CROHN'S DISEASE. THE ENIGMA STUDY (2022) (0)
experience . in inflammatory bowel disease : 27 years of Bone marrow toxicity caused by azathioprine (2006) (0)
Sa1143 Need for Recurrent Resection and Complex Phenotype Are Associated With a Specific Antibody Signature in Crohn's Disease Patients Undergoing Resection; Smoking Is Not Associated With Prevalent Antibodies; Prognostic and Mechanistic Implications (2015) (0)
P458 the microbiota in crohn's disease and health is it the same in the east and west? the effects of geography, ethnicity and disease on microbiota (2012) (0)
219 Incidence and Phenotype At Diagnosis of Inflammatory Bowel Disease Across 9 Countries in Asia-Pacific (2013) (0)
Genetics of Inflammatory Bowel Disease in Asia: Systematic Review and Meta-Analysis (2011) (0)
Tu1255 MICROBIOTA AND VIRUENCE FACTORS ASSOCIATED WITH CROHN'S DISEASE RECURRENCE REVEALED AT STRAIN-LEVEL RESOLUTION BY NOVEL COMBINATION OF MICROBE CULTURE AND METAGENOMIC SEQUENCING (MC-MGS). THE ENIGMA STUDY (2020) (0)
Production of interleukin-10 by human intestinal dendritic cells is upregulated by probiotic bacteria (2003) (0)
The structure, function, and pathology of the thyroid gland (0)
P185 Increased Gut Plasmacytoid Dendritic Cells in Acute Ulcerative Colitis - Key Mediators Of Immunity and Inflammation? (2007) (0)
S1320 Multi-Center, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Sodium Picosulfate (SPS) in Patients With Chronic Constipation (2010) (0)
Response to Savoye and Savoye-Collet (2010) (0)
Patey Prize 02 (2009) (0)
Signaltrassduction-factor NFκB p65 is activated in patients with chronic relapsing pouchitis through probiotic therapy although healing occurs (2001) (0)
Reply: To PMID 25167986. (2015) (0)
Reply (1993) (0)
Clinical outcomes among elderly patients with inflammatory bowel disease. (2022) (0)
A cc ep te d A rti cl e PARENT HOSTILITY AND SPIN-OUT PERFORMANCE (2013) (0)
T1350 Pudendal Nerve Stimulation for Bowel Dysfunction Secondary to Spinal Cord Injury (2010) (0)
P316 - TNF-α production and differential release of Th1/Th2 cytokines detected in colonic tissues of inflammatory bowel disease patients but not controls (2009) (0)
Tu1289 Preventing Crohn's Disease Recurrence After Resection With Adalimumab: Role of Drug and Anti-Drug Antibody Levels (2015) (0)
Mo1745 The Microbiota in Crohn's Disease and Health - is it the Same in the East and West? the Effects of Geography, Ethnicity and Disease on Microbiota (2012) (0)
426 FURTHER EVIDENCE THAT PROTEUS MIRABILIS IS A KEY BACTERIUM IN CROHN'S DISEASE PATHOGENESIS. THE ENIGMA STUDY. (2020) (0)
Food, prebiotics and bacteria (2002) (0)
Behavioural therapy (biofeedback) for solitary rectal ulcer syndrome improves symptoms, mucosal blood flow and can produce healing (2003) (0)
Gut-specific autonomic testing can be used to predict bowel dysfunction in spinal cord injury patients (1998) (0)
Bonemarrow toxicity caused byazathioprine in inflammatory bowel disease: 27years ofexperience (2017) (0)
Clinical risk stratification accurately predicts development of endoscopic recurrence after Crohn (2012) (0)
RISK FACTORS FOR SUBSEQUENT INTESTINAL RESECTIONS IN PATIENTS WITH CROHN'S DISEASE (2008) (0)
Pharmaceutical composition comprising a topical cholinergic agent or a calcium channel blocker (1998) (0)
PP1700 大腸憩室症におけるMatrix MetalloproteinaseとTissue Inhibitor of Metalloproteinaseの検討 (2001) (0)
Subject Index Vol. 60, 1999 (1999) (0)
Summary and observations (2002) (0)
T1162 The Concentration and Proportion of Key Bacterial Groups of the Faecal Microbiota Are Different Between Smokers and Non-Smokers with Active Crohn's Disease (2008) (0)
Inflammatory Bowel Diease: East Meets West: Falk Symposium 198, Shenzhen, September 2015: Official Congress Report (2016) (0)
P749 Crohn’s disease stricture response and resolution with adalimumab therapy demonstrated with intestinal ultrasound. The STRIDENT randomised trial (2023) (0)
Tegaserod is safe and well tolerated in patients with chronic constipation: results from a 12-week multinational study (2003) (0)
S1750 Distinct Cytokine Patterns from Multiplex Profiles of Patients with Inflammatory Bowel Disease, Functional Bowel Disorder and Healthy Controls (2009) (0)
DOP49 Metagenomic Characterisation of The Colonic Mucosa-Associated Microbiota Reveals Novel Microbes and Communities in Health and Crohn’s disease. The ENIGMA study (2023) (0)
DOP34 Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn’s Disease for modified Rutgeerts’ score i2a and i2b categories: Individual patient data meta-analysis (2022) (0)
P056 Number Needed To Treat With MMX Mesalazine For One Patient With Mild-To-Moderate Ulcerative Colitis To Achieve Remission (2007) (0)
M1236 Prevalence of Self-Defined Constipation and Laxative Use Among Adults from South America and Asia (2009) (0)
Co-stimulatory molecule expression on gut dendritic cells (DC) is upregulated in inflamed tissue from Crohn's disease - a possible early and central step in driving T cell activation (2000) (0)
96. Dual isotope gastric emptying and colonic transit: development of a scanning protocol (1992) (0)
New therapeutic possibilities in inflammatory bowel disease. (2001) (0)
M1804 Pharmacist Attitudes About Constipation and Its Treatment: A Survey Conducted in Three Countries (2008) (0)
P053 Prolonged Therapy with MMX™ Mesalazine in Patients with Acute, Mild-to-Moderate Ulcerative Colitis Who Fail Initial Mesalazine Treatment may Avoid the Need for Therapeutic Escalation (2008) (0)
OC-011 Demographic, clinical and genetic factors associated with dysbiosis in patients with active Crohn's disease (2010) (0)
Symptom resolution with MMX® mesalazine in patients with mild-to-moderately active ulcerative colitis who are newly diagnosed or have been living with their disease for a prolonged period (2010) (0)
P511 Radiological outcomes in perianal fistulising Crohn’s disease (2019) (0)
P669 Improving Crohn’s disease stricture dilation outcome: Effect of repeated dilation, needle knife stricturotomy, and ongoing active inflammation (2023) (0)
O-027: Sustainability of adalimumab in fistula healing and response: 2-year data from CHARM and an open-label extension follow-up study (2008) (0)
Loss of mucosal CD1a+ dendritic (antigen presenting) cells in inflammatory bowel disease (1998) (0)
261 – Proteus is a Key Candidate in the Pathogenesis of Crohn's Disease: Mucosa, Stool Genomics and Functional Analysis: the Enigma Study (2019) (0)
DOP85 Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled Trial (2023) (0)
Sa1387 Long-Term Follow-Up of a Prospective, Open, Multicenter Cohort Study of Sacral Neuromodulation for Intractable Constipation (2015) (0)
P312 Thiopurine metabolite testing in inflammatory bowel disease (2014) (0)
P852 Characterisation of Crohn’s disease mucosa-associated microbiota by a novel combination of microbe culture and metagenomic sequencing (MC-MGS): the ENIGMA study (2019) (0)
P575 Simple novel tacrolimus enemas are very effective in severe refractory proctitis (2019) (0)
Author's response (2010) (0)
P320 6-Thioguanine nucleotide levels are associated with trough levels of infliximab and adalimumab in Inflammatory Bowel Disease patients on combination therapy: A retrospective multicentre study (2022) (0)
P015 THALIDOMIDE IN LUMINAL AND FISTULISING CROHN'S DISEASE RESISTANT TO STANDARD THERAPIES (2007) (0)
Intestinal bacteria and mechanisms of disease (2002) (0)
OC-003 No clinical benefit of prebiotics in the treatment of active Crohn's disease: a double-blind, randomised, placebo-controlled trial (2010) (0)
Subject Index Vol. 57, 1996 (1996) (0)
P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis (2020) (0)
MMXTM mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis: P-045. (2008) (0)
P523 Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohn’s disease (2019) (0)
Prospective evaluation of the relationship between stress and relapse in ulcerative colitis. (2008) (0)
Bowelfunction andtransit rateduring the menstrual cycle (1989) (0)
Pharmaceutical compositions for the treatment of fecal incontinence and analklöe (1997) (0)
P925 Deep functional assessment of the colonic mucosa-associated microbiota in Crohn's disease and health identifies pro- and anti- inflammatory secretomes and associated bacterial consortia. The ENIGMA study (2023) (0)
Kamm with a functional gut disorder of activity of extrinsic gut innervation in patients Relationship between psychological state and level (2001) (0)
Adalimumab induction therapy achieves clinical remission and response in chinese patients with Crohn's Disease (2015) (0)
SYMPOSIUM ON FAECAL INCONTINENCE (2001) (0)
Manometry, Electromyography and Other Functional Pelvic Floor Tests (1993) (0)
Prospective Evaluation of the Mucosa-Associated Microbiota After “Curative” Crohn's Resection Reveals Incomplete Return to “Normal” and Association of Bacteroides With Protection From Disease Recurrence (2011) (0)
P766 Practical application of evidence-based dietary therapy into inflammatory bowel disease care shows high patient satisfaction, compliance, and efficacy. The Delectable Program (2023) (0)
W1357 Cross-Sectional Study On the Correlation Between Pre-Operative Azathioprine and Myenteric Plexitis in the Proximal Resection Margins and Affected Crohn's Disease Segment (2008) (0)
Gastro-esophageal reflux and motility: implications for management. (1994) (0)
Anti-TNF therapy: a fulfilment of great expectations (2002) (0)
Ulcerative Colitis at Diagnosis is More Extensive Anatomically in the East (China) Than the West (Australia) and is Managed Differently. (2011) (0)
Constipation. Kamm M.A., Lennard‐Jones J.E., eds. Wrightson Biomedical Publishing, 1994 (1995) (0)
534 – Mri is Highly Predictive of the Clinical Course of Crohn's Disease Strictures (2019) (0)
P059 MMX MESALAZINE IS AN EFFECTIVE TREATMENT FOR ACTIVE, MILD-TO-MODERATE UC REGARDLESS OF PRIOR 5-ASA USE: A POOLED ANALYSIS OF TWO PLACEBO-CONTROLLED, PHASE III TRIALS (2007) (0)
PTH-034 Stress-induced immunomodulation in irritable bowel syndrome suppresses Th1 and Th2 cytokines (2010) (0)
Book review (2005) (0)
Su1581 Endoscopic Outcomes After Ileo-Caecal Resection for Crohn's Disease: A Prospective Single Tertiary Centre Study (2011) (0)
P538 Suboptimal disease control is common in patients with Crohn’s perianal fistulas with capacity to optimise medical and surgical treatment in real-world experience: A cross-sectional analysis of baseline disease characteristics in the FINESS study (2023) (0)
Tu1869 – Characterization of Crohn's Disease Mucosa-Associated Microbiota by a Novel Combination of Microbe Culture and Metagenomic Sequencing (MC-MGS). the Enigma Study (2019) (0)
IBD Basic Science (2022) (0)
Clinical features and outcomes of adult idiopathic megarectum (2023) (0)
397: FOOD ADDITIVES INTAKE IS ASSOCIATED WITH MICROBIOME DYSBIOSIS AND SPECIFIC PRO-INFLAMMATORY BACTERIAL CHANGES IN CROHN'S DISEASE. THE ENIGMA STUDY. (2022) (0)
Colonic motility and functional diseases (1991) (0)
Abnormalities of the Neural Control of the Internal Anal Sphincter in Idiopathic Faecal Incontinence (1992) (0)
Endoscopic and histological disease activity in ulcerative colitis is associated with nonresponse to biological therapy (2019) (0)
Crohn’s disease: towards improving postsurgical outcomes. (2013) (0)
Impact of steroid discontinuation on health care resource utilization in Crohnʼs disease: P-011. (2008) (0)
Arthropathy of inflammatory bowel disease and the effect of restorative proctocolectomy (1995) (0)
Approach to Dietary Restriction in Irritable Bowel Syndrome. (2021) (0)
Composition pharmaceutique destinee au traitement de l'incontinence fecale et du prurit anal (1997) (0)
EP1308: 6-THIOGUANINE NUCLEOTIDE LEVELS AND ANTI-TNFα TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE PATIENTS ON COMBINATION THERAPY: A RETROSPECTIVE MULTICENTRE STUDY (2022) (0)
Satisfaction with therapy among patients treated with MMXTM mesalamine for maintenance of remission in patients with mild-to-moderate ulcerative colitis: P-044. (2008) (0)
MRI Guided Biologic Therapy for Crohn's Perianal Fistulae: 3 Year Follow up Data (2011) (0)
Intestine mucosal IL‐22 is reduced following oral probiotic administration: implications on epithelial barrier repair (2013) (0)
Crohn ' s disease . Lower gastrointestinal malignancy in (2006) (0)
Utility of a simple blood test for mucosal healing monitoring is accurate in postoperative Crohn's disease (2019) (0)
Mo1926 - Donor Characteristics and Clinical Outcomes of Fecal Microbiota Transplantation: A Systematic Review of Clinical Studies Published Up to 2017 (2018) (0)
Letter: management of post‐operative Crohn's disease ‐ thiopurines vs adalimumab– authors' reply (2016) (0)
DOP48 Key Anti-Inflammatory Faecalibacterium prausnitzii is Heterogeneous and Diverse in the East and West and in Health and Crohn’s disease. The ENIGMA study (2023) (0)
P309 - Altered imprinting of lymphocyte homing by colonic dendritic cells in human ulcerative colitis (2009) (0)
Relationship Between Serum Ustekinumab Trough Concentration and Clinical and Biochemical Disease Activity: A Real-World Study in Adult Patients with Crohn's Disease. (2023) (0)
Induction of remission with extended MMXTM mesalamine therapy: time to resolution of UC symptoms: P-0026. (2008) (0)
Drug management of ulcerative colitis: Author's reply (1992) (0)
A pharmaceutical preparation for the treatment of anal incontinence and anal itch (1997) (0)
Probiotic Bacteria Differentially Modulate the Maturation and Cytokine Expression of Human Dendritic Cells (2003) (0)
Plummer & Vinson of the Plummer-Vinson syndrome (1999) (0)
visceral fat as a predictor of post‐operative recurrence of Crohn's disease—Authors’ reply (2017) (0)
Mo1789 - The “Assurance” IBD Neoplasia Surveillance Software Guides Patient Management and Data Collection: Results from Asia-pacific (2018) (0)
MMX mesalamine, a novel formulation, effectively induces remission of mild-tomoderate ulcerative colitis: a pooled analysis of two phase III studies: P-0079. (2007) (0)
Tu1775 – The Nod2 Association with Cd-Associated Serological Markers is Modulated by Its Effect on Gut Microbiome (2019) (0)
Reply (1997) (0)
Prolonged MMX® mesalazine therapy in patients with acute, mild-to-moderate ulcerative colitis who fail initial mesalazine treatment may prevent a requirement for therapeutic escalation (2010) (0)
DNA viruses inthepathogenesis ofsporadic chronic idiopathic intestinal pseudo-obstruction (1997) (0)
P773 Post-operative Crohn's disease recurrence is associated with specific changes in the faecal microbiome - potential pathogenic and protective roles. (2017) (0)
Tu1497: COMPARISON OF THE RISK OF CLINICAL RECURRENCE AFTER ILEOCOLONIC RESECTION FOR CROHN'S DISEASE FOR MODIFIED RUTGEERTS’ SCORE I2A AND I2B CATEGORIES: INDIVIDUAL PATIENT DATA META-ANALYSIS. (2022) (0)
Physiology and Pathophysiology of Defaecation (1993) (0)
P587 Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) for monitoring of response to therapy in luminal Crohn’s disease – a systematic review (2023) (0)
The normal flora and techniques of identification (2002) (0)
Sa533 NOVEL CHARACTERIZATION OF THE SECRETOMES OF CROHN'S DISEASE MUCOSA-ASSOCIATED MICROBIOTA, AND THEIR MODULATION OF INFLAMMATION THROUGH NF-κB SIGNALLING. THE ENIGMA STUDY. (2021) (0)
Low failure to attend rates and increased clinic capacity with Telehealth: A highly effective outpatient model that should continue beyond the COVID‐19 pandemic (2020) (0)
Adalimumab Therapy Achieves Clinical Remission and Response at Week 26 in Chinese Patients With Crohnʼs Disease: 1874 (2015) (0)
A six-month open label evaluation of CDP571, a humanized antibody to TNFa, in active Crohn's disease (2000) (0)
Validation of the Inflammatory Bowel Disease Disk in clinical practice (2019) (0)
P121 Long-Term Outcome and Adverse Events in Crohn's Disease Patients Treated with Infliximab at a Single Tertiary Referral Centre (2008) (0)
constipation Sacral nerve stimulation for intractable (0)
Association of Complete Spontaneous Bowel Movements (CSBM) and Symptom Improvement in Chronic Constipation (CC) Patients (PTS): 931 (2005) (0)
FORTHCOMING ARTICLES MARCH 2010 (2009) (0)
P558 Validation of the ‘IBD Disk’ in clinical practice (2020) (0)
P166 THE EFFICACY OF MMX™ MESALAZINE AS THE SOLE MEDICATION FOR THE INDUCTION AND MAINTENANCE OF REMISSION IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS TREATED OVER 14-16 MONTHS (2008) (0)
Letters Author's Reply (0)
Manipulation of enteric flora in clinical practice (2005) (0)
EP1283: NOVEL FAECAL MICROBIOME SIGNATURES AS NON-INVASIVE BIOMARKERS FOR DIAGNOSIS OF CROHN'S DISEASE AND AT-RISK POPULATIONS (2022) (0)
Non-surgical of faecal incontinence (2001) (0)
Dendritic Cells Migration and Maturation of Human Colonic (2001) (0)
P158 Outcome of inflammatory bowel disease strictures (2018) (0)
Reply: To PMID 25542620. (2015) (0)
P195 MRI is predictive of, and anti-TNF treatment changes, the clinical course of Crohn's disease strictures (2019) (0)
Contents Vol. 57, 1999 (1999) (0)
Evaluation and management of ileal pouch-anal anastamosis (IPAA) complications in pregnancy, and the impacts of an IPAA on fertility. (2023) (0)
COMPARISON OF TWO DIFFERENT METHODS FOR THE DETERMINATION OF 5-AMINOSALICYLIC ACID IN HUMAN INTESTINAL SAMPLES BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY AND ELECTROCHEMICAL DETECTION (2008) (0)
ASSURANCE: a multi-centre practical and systematised approach to colorectal cancer surveillance in patients with inflammatory bowel disease (2016) (0)
Erratum: (Gastroenterology (1999) 166 (735-760)) (1999) (0)
Tu1489: STRAIN-LEVEL RESOLUTION OF THE COLONIC MUCOSA-ASSOCIATED MICROBIOTA REVEALS NOVEL TRANS-ETHNIC DIFFERENCES IN HEALTH AND CROHN'S DISEASE. THE ENIGMA STUDY. (2022) (0)
P047 - Prospective assessment of the effect on quality of life of healing perineal Crohn's fistulas with anti-tumour necrosis factor therapy (2009) (0)
Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study (2022) (0)
Prospective Evaluation of the Mucosa-Associated Microbiota Using 454 Pyrosequencing at Crohn's Surgery and 6 Months Later Reveals Loss of Diversity and Specific Phyla Changes Associated With Disease Recurrence (2011) (0)
Effect of food additives on key bacterial taxa and the mucosa-associated microbiota in Crohn’s disease. The ENIGMA study (2023) (0)
Authors' reply (2000) (0)
Nurse-led, protocol-driven screening for hepatitis B virus before initiating biological therapy for chronic inflammatory disease is very effective (2019) (0)
Pathogenesis of Crohn's disease (1992) (0)
Escalating incidence of IBD in the East and West - Is the microbiota the key? impact of ethnicity, geography, and disease on the microbiota. The ENIGMA study (2013) (0)
P265 Intestinal Dendritic Cells in Ulcerative Colitis Have Altered CD103 (α-E) Expression Supporting Dysregulation in Gut-Homing (2008) (0)
Are biological drugs effective enough (2007) (0)
Su1530 Narrow Band Imaging (NBI) Versus Chromoendoscopy for Dysplasia Detection in Colitis Surveillance: Double-Blind Comparison (2011) (0)
Spontaneous production of pro-inflammatory cytokines by colonic biopsies is altered by treatment of Crohn's disease patients with anti-TNFa antibody (2000) (0)
Comparison of Fecal In fl ammatory Markers in Crohn ’ s Disease (0)
T2068 Suppression of TH1 and TH2 Cytokines in Patients With Irritable Bowel Syndrome- Evidence of a Chronic Stress Immunophenotype? (2010) (0)
Urinary Bladdar Cancer In Jordan: An Epidemiologic Study (1981) (0)
Both high-dose (4.8g/day) induction and low-dose (2.4g/day) maintenance therapy with MMXTM mesalamine have an excellent safety profile in patients with mild-to-moderate ulcerative colitis: P-028. (2008) (0)
Steroid-Free remission in response to Adalimumab therapy over 2 years in patients with Crohnʼs Disease: Results From open-label extension of the CHARM trial: P-0075. (2008) (0)
Book reviews (2004) (0)
Therapeutic advances and issues of patient adherence in the treatment of ulcerative colitis (2007) (0)
Editorial: visceral fat as a predictor of post‐operative recurrence of Crohn's disease—Authors’ reply (2017) (0)
P589 Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. (2017) (0)
EP1273: PRACTICAL APPLICATION OF EVIDENCE-BASED DIETARY THERAPY INTO INFLAMMATORY BOWEL DISEASE CARE. PATIENT SATISFACTION, COMPLIANCE, AND EFFICACY. THE DELECTABLE PROGRAM. (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael A Kamm?

Michael A Kamm is affiliated with the following schools:

University of California, Berkeley
University of Melbourne
Stanford University